Cargando…

Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [(64)Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial

BACKGROUND: Quantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has a direct anti-inflammatory effect in the coronary arteries using positro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Jacob K., Zobel, Emilie H., von Scholten, Bernt J., Rotbain Curovic, Viktor, Hansen, Tine W., Rossing, Peter, Kjaer, Andreas, Ripa, Rasmus S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669791/ https://www.ncbi.nlm.nih.gov/pubmed/34917038 http://dx.doi.org/10.3389/fendo.2021.790405

Ejemplares similares

Effect of Liraglutide on Vascular Inflammation Evaluated by [(64)Cu]DOTATATE
por: Zobel, Emilie H., et al.
Publicado: (2021)

Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
por: Zobel, Emilie H, et al.
Publicado: (2021)

Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
por: Wretlind, Asger, et al.
Publicado: (2022)

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
por: Zobel, Emilie H., et al.
Publicado: (2021)

[(64)Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans
por: Jensen, Jacob K., et al.
Publicado: (2022)

Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials
por: Wretlind, Asger, et al.
Publicado: (2023)

Effect of Liraglutide on Arterial Inflammation Assessed as [(18)F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Ripa, Rasmus S., et al.
Publicado: (2021)

[(68)Ga]Ga-NODAGA-E[(cRGDyK)](2) and [(64)Cu]Cu-DOTATATE PET Predict Improvement in Ischemic Cardiomyopathy
por: Follin, Bjarke, et al.
Publicado: (2023)

(64)Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques: Studies in Patients Undergoing Endarterectomy
por: Pedersen, Sune Folke, et al.
Publicado: (2015)

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment
por: Zobel, Emilie H., et al.
Publicado: (2019)

A convolutional neural network for total tumor segmentation in [(64)Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms
por: Carlsen, Esben Andreas, et al.
Publicado: (2022)

Initial Experience with (64)Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET
por: Loft, Mathias, et al.
Publicado: (2021)

(64)Cu-DOTATATE Positron Emission Tomography (PET) of Borrelia Burgdorferi Infection: In Vivo Imaging of Macrophages in Experimental Model of Lyme Arthritis
por: Skovsbo Clausen, Anne, et al.
Publicado: (2020)

Non‐invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls
por: Rasmussen, Ida K. B., et al.
Publicado: (2021)

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls
por: Laursen, Jens Christian, et al.
Publicado: (2021)

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
por: Sivalingam, Suvanjaa, et al.
Publicado: (2021)

FRI265 I123-MIBG Positive, CU64-Dotatate PET Negative Pheochromocytoma In A Patient With Bilateral Adrenal Incidentalomas
por: Pagadala, Prathyusha, et al.
Publicado: (2023)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

Myocardial flow reserve assessed by cardiac (82)Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes
por: Zobel, Emilie H, et al.
Publicado: (2019)

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial
por: Curovic, Viktor Rotbain, et al.
Publicado: (2023)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1 Diabetes
por: Curovic, Viktor Rotbain, et al.
Publicado: (2020)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Theragnostic (64)Cu/(67)Cu Radioisotopes Production With RFT-30 Cyclotron
por: Lee, Jun Young, et al.
Publicado: (2022)

The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials
por: Zobel, Emilie H., et al.
Publicado: (2021)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
por: Rotbain Curovic, Viktor, et al.
Publicado: (2022)

Pharmacokinetic Analysis of (64)Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice
por: Li, Fan, et al.
Publicado: (2015)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

Editorial: Advanced Cardiovascular Imaging in Diabetes
por: Schick, Fritz, et al.
Publicado: (2022)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [(64/67)Cu]Cu-SARTATE
por: Laffon, Eric, et al.
Publicado: (2021)

Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes
por: Zobel, Emilie H., et al.
Publicado: (2020)

The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model
por: Rylova, Svetlana N., et al.
Publicado: (2018)

[(64)Cu]‐labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice
por: Schjoeth‐Eskesen, Christina, et al.
Publicado: (2015)

PET/CT Based In Vivo Evaluation of (64)Cu Labelled Nanodiscs in Tumor Bearing Mice
por: Huda, Pie, et al.
Publicado: (2015)

The pathophysiology of Wilson’s disease visualized: A human (64)Cu PET study
por: Sandahl, Thomas Damgaard, et al.
Publicado: (2022)

Imaging of atherosclerosis with [(64)Cu]Cu-DOTA-TATE in a translational head-to-head comparison study with [(18)F]FDG, and Na[(18)F]F in rabbits
por: Grandjean, Constance E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cg3ijdrn9i3qia847va05inh0s